StockNews.com Initiates Coverage on TherapeuticsMD (NASDAQ:TXMD)

Equities research analysts at StockNews.com started coverage on shares of TherapeuticsMD (NASDAQ:TXMD) in a research report issued to clients and investors on Wednesday. The firm set a “hold” rating on the stock.

TherapeuticsMD Stock Up 0.7 %

Shares of TherapeuticsMD stock opened at $1.41 on Wednesday. TherapeuticsMD has a 12-month low of $1.15 and a 12-month high of $2.99. The stock’s fifty day moving average is $1.55 and its 200-day moving average is $1.75.

Institutional Inflows and Outflows

An institutional investor recently raised its position in TherapeuticsMD stock. Clearline Capital LP increased its position in TherapeuticsMD, Inc. (NASDAQ:TXMD) by 18.9% in the second quarter, according to its most recent 13F filing with the SEC. The firm owned 636,622 shares of the company’s stock after purchasing an additional 101,282 shares during the period. Clearline Capital LP owned about 5.52% of TherapeuticsMD worth $1,025,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 30.74% of the company’s stock.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.